Modiblast

📢 Looking forward to pitching our investment case at the upcoming #BayOConnect conference on June 2nd in #Munich. ⬇ Our Founder and CEO/CSO Helga Schmetzer will provide a snapshot of our #cellreprogramming strategy in AML/MDS and share our wider vision behind Modiblast's novel therapeutic approach. Modiblast is entering a transformative period with its lead development program MB101 steadily progressing towards IND-readiness. MB101 combines #cytokine and #prostaglandine pathway modulation to reprogram leukemic blast cells and elicit a comprehensive and sustained anti-tumor immune response. Thanks to BioM Biotech Cluster Development GmbH for having us and good luck to all our fellow presenters. #BayOConnect2024 #startups #AMLmaintenance #cancerresearch

😮 Oh my goodness!! ⏳ There are only 4 weeks to go until #BayOConnect, the Bavarian platform for experiencing the 💉 #futureofmedicine. Join us on 2-3 July, when Bavarian #biotechnology, #startups, #SMEs, #bigplayer in data, #investors and other biotechnology enthusiasts meet to discuss the future of medicine: ➡️ https://lnkd.in/dGMqmzYS Together, we 🔴 exchange ideas on how to bring #AI-, data-driven #medicine from #science to application. 🔴 learn how to #finance these development paths. 🔴 see which💡#innovations are already shaping today's medical practice as applications. 🔴 see which 🚀 start-ups are launching the #nextbigthing in medicine and #drugdevelopment and with which ideas. 🔴 learn about the additional benefits and potential of AI and data - for 🧑⚕️ #therapies and in drugdevelopment. 🔴 discuss how AI and #repurposing can influence #precisionmedicine. 👉 "Shape with us the future of biotech!" 👈 #BayOConnect2024 #BiotechnologyConference #Innovation #AI4Medicine #AI4Health #AI4Biotech #bigdata

And it appears as if interest in #DendriticCells research is growing.

Read about this #DendriticCells review in Nature.

Has the antigen-presenting role of #DendriticCells been underestimated in #cancer #immunotherapy? In this new review, Ignacio Heras Murillo, Stefanie K. Wculek, David Sancho Madrid and colleagues highlighted novel insights on DCs derived from patients with different cancers and single-cell studies of DCs that have relevance to therapeutic strategies. Nature Portfolio "Dendritic cells (#DCs) are a heterogeneous group of #antigenpresenting #innateimmune cells that regulate adaptive immunity, including against cancer. Therefore, understanding the precise activities of DCs in #tumours and patients with cancer is important. The classification of DC subsets has historically been based on ontogeny; however, #singlecell analyses are now additionally revealing a diversity of functional states of DCs in cancer." "DCs can promote the activation of potent #antitumour #Tcells and #immuneresponses via numerous mechanisms, although they can also be hijacked by tumour-mediated factors to contribute to #immunetolerance and #cancerprogression. Consequently, DC activities are often key determinants of the efficacy of #immunotherapies, including #immunecheckpoint inhibitors. Potentiating the antitumour functions of DCs or using them as tools to orchestrate short-term and long-term #anticancer immunity has immense but as-yet underexploited #therapeutic potential." "In this Review, we outline the nature and emerging complexity of DC states as well as their functions in regulating #adaptiveimmunity across different #cancertypes. We also describe how DCs are required for the success of current immunotherapies and explore the inherent potential of targeting DCs for #cancertherapy. We focus on novel insights on DCs derived from patients with different cancers, single-cell studies of DCs and their relevance to #therapeuticstrategies." #clinicaloncology #oncology #immunooncology #immunology #cancerimmunotherapy #klinischeonkologie #onkologie #immunonkologie #immunologie #immuntherapien #krebsimmuntherapien #krebs #krebsforschung #medicalresearch #medicalscience #translationalscience #translationalresearch #clinicaldevelopment Heras-Murillo, I., Adán-Barrientos, I., Galán, M. et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol 21, 257–277 (2024). DOI: 10.1038/s41571-024-00859-1 https://lnkd.in/esRwi7UE

In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine developed at the University of Florida quickly reprogrammed the immune system to attack glioblastoma, the most aggressive and lethal brain tumor.

Reflecting on #EBMT24, we're happy to witness how strong this platform is for collaboration and sharing invaluable knowledge and scientific insights, all aimed at enhancing #patient care. 👩⚕️ Dive into some highlights in the latest EBMT TV 📺 short video ➡️ https://lnkd.in/ejaET7EW

Our CEO Helga Schmetzer will be there starting tomorrow. Watch out to find her or contact through the partnering tool. Please consider that we are mainly looking for real funding, not CROs or fundraiser consultants.

Meet our CEO Helga Schmezer at #bioeurope spring in Barcelona next week! Especially if you are interested in investing in a startup with granted patents, a clear benefit for an unmet and urgent medical need, and a plan for development to get a new therapy approach to approval.

🚨 IT'S OFFICIALLY RARE DISEASE DAY ACROSS THE GLOBE 🚨 Join us in marking Rare Disease Day 2024 now that it's finally here! Let's unite in solidarity with the millions worldwide living with rare diseases. 🌍 Spread awareness, share stories, and show support for them. Together, we can make a lasting impact and shine a light on these often overlooked! Let's make today count by raising awareness and advocating for those who need it most. Every voice matters in the fight for understanding and support. Visit our website to find out more:https://lnkd.in/gk6hbAF . . #RareDiseaseDay #ShareYourColours #LightUpForRare #Awareness